Experimental ex vivo lung perfusion with sevoflurane: effects on damaged donor lung grafts.

Détails

ID Serval
serval:BIB_83A60B7388D4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Experimental ex vivo lung perfusion with sevoflurane: effects on damaged donor lung grafts.
Périodique
Interactive cardiovascular and thoracic surgery
Auteur(s)
Wang X., Parapanov R., Francioli C., Perentes J.Y., Letovanec I., Gonzalez M., Kern C., Ris H.B., Piquilloud L., Marcucci C., Krueger T., Liaudet L., Gronchi F.
ISSN
1569-9285 (Electronic)
ISSN-L
1569-9285
Statut éditorial
Publié
Date de publication
01/06/2018
Peer-reviewed
Oui
Volume
26
Numéro
6
Pages
977-984
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Volatile anaesthetics can provide significant protection against reperfusion injury in various experimental settings. The aim of this study was to assess the potential of sevoflurane treatment, the most commonly used volatile anaesthetic in modern anaesthesia, in rat lungs donated after circulatory death and reconditioned in an ex vivo lung perfusion (EVLP) system.
Fifteen rats were sacrificed and divided into 3 groups. In the control and sevoflurane groups, the heart-lung blocks were exposed to 1 h of warm ischaemia and 2 h of cold ischaemia and were mounted on an EVLP circuit for 3 h, in the absence or in the presence of 2% sevoflurane. In the baseline group, heart-lung blocks were harvested immediately after euthanasia. Physiological data, lung nitro-oxidative stress, lactate dehydrogenase (LDH), expression of cytokines, oedema and histopathological findings were assessed during or post-EVLP.
The sevoflurane group showed significantly reduced LDH (8.82 ± 3.58 arbitrary unit vs 3.80 ± 3.02 arbitrary unit, P = 0.03), protein carbonyl (1.17 ± 0.44 nmol⋅mg-1 vs 0.55 ± 0.11 nmol⋅mg-1, P = 0.006), 3-nitrotyrosine (197.44 ± 18.47 pg⋅mg-1 vs 151.05 ± 23.54 pg⋅mg-1, P = 0.004), cytokine-induced neutrophil chemoattractant factor 1 (1.17 ± 0.32 ng⋅mg-1 vs 0.66 ± 0.28 ng⋅mg-1, P = 0.03) and tumour necrosis factor alpha (1.50 ± 0.59 vs 0.59 ± 0.38 ng⋅mg-1, P = 0.02) when compared with the control group. In addition, sevoflurane lungs gained significantly less weight (0.72 ± 0.09 g vs 0.72 ± 0.09 g, P = 0.044), had less perivascular oedema (0.58 ± 0.09 vs 0.47 ± 0.07, P = 0.036), and improved static pulmonary compliance (+0.215 ml⋅cmH2O-1, P = 0.003) and peak airways pressure (-1.33 cmH2O, P = 0.04) but similar oxygenation capacity (+1.61 mmHg, P = 0.77) and pulmonary vascular resistances (+0.078 mmHg⋅min⋅ml-1, P = 0.15) when compared with the control group.
These findings suggest that the potential of sevoflurane in protecting the lungs donated after cardiac death and reconditioned using EVLP could improve the outcome of these lungs following subsequent transplantation.
Mots-clé
Anesthetics, Inhalation/administration & dosage, Animals, Disease Models, Animal, Extracorporeal Circulation, Lung/physiopathology, Lung Transplantation/adverse effects, Male, Perfusion/methods, Rats, Reperfusion Injury/therapy, Sevoflurane/administration & dosage, Tissue Donors
Pubmed
Web of science
Création de la notice
30/01/2018 9:03
Dernière modification de la notice
20/08/2019 14:43
Données d'usage